Stockreport

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences [Yahoo! Finance]

I-MAB - American Depositary Shares  (IMAB) 
PDF New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate acces [Read more]